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A B S T R A C T
Background: For many years, ERCP was avoided in pregnancy given the concerns regarding the adverse
effects that, with special focus on radiation, could occur in the developing fetus. However, the
postponement or rejection of ERCP in pregnant women, may lead to a higher risk for mother and fetus,
especially when the indication is unequivocal, namely cholangitis, biliary pancreatitis and symptomatic
choledocholithiasis.
Summary and key messages: This review aims to summarize the scarce literature on the subject in order to
plan ERCP in pregnancy with the highest safety. The use of techniques that reduce radiation and increase
the protection of pregnant women allow radiation levels far below the safety limits.
We also discuss the various alternatives of ERCP without radiation. EUS can eliminate the need for ERCP
with doubtful choledocholithiasis and plan the best approach in those with previous evidence. The
possibility of performing “ERCP” with a linear echoendoscope uniquely under ultrasound control has
been described. Conversely, the two-step strategy (initial sphincterotomy with stent placement without
fluoroscopy and after delivery, ERCP with lithiasis extraction) proved to be safe obviating fluoroscopy. In
conclusion, ERCP can be performed in pregnancy safely and effectively with minimal radiation or even
no-radiation at all.
© 2017 Elsevier B.V. All rights reserved.
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Women are about twice as likely to develop choledocholithiasis
compared to men, regardless of the prevalence of cholelithiasis [1].
This discrepancy is more pronounced at younger ages, with a
significant reduction in the woman-to-man ratio as the age
progresses [2], reflecting the magnitude of the effect of pregnancy
and sex hormones.
The litogenicity of female sex hormones is reinforced by studies
in which estrogens have been administered to men. In a study with
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hepatic cholesterol secretion that resulted in an increase in both
bile cholesterol saturation and rate of gallstone formation during
estrogen treatment [3]. Also, in men with acute myocardial
infarction, estrogens increased the risk of biliary lithiasis more
than twice [4].
Pregnancy is a major risk factor for biliary lithiasis. The risk
increases with frequency and number of pregnancies and reduces
with breastfeeding [5]. The risk increases up to 10 times in
multiparous compared to nulliparous [6]. During pregnancy there
is a decrease in gallbladder motility and a breakdown of cholesterol
in bile. These changes are induced by estrogen which increases
cholesterol secretion and progesterone which reduces the secre-
tion of bile acids and delays the emptying of the gallbladder. There
is also a relative overproduction of hydrophobic bile acids
(chenodeoxycholate) which reduces bile's ability to solubilize
cholesterol [1,7].
In a prospective ultrasound study with more than 3200
pregnant women without lithiasis (baseline ultrasound), lithiasis
or new bile sludge was observed in 7.1% up to the second trimester,
7.9% up to the third trimester and 10.2% up to 6 weeks postpartum.
Of the pregnant women with lithiasis or biliary sludge, only 1.2%
developed symptoms of biliary pathology [8]. Up to 10% of
symptomatic pregnant women develop serious complications
such as acute cholecystitis, choledocholithiasis or pancreatitis [9].
Risks of ERCP in pregnancy include risks of sedation, radiation
or electrocautery to the fetus, as well as technical difficulties
related to the changing maternal anatomy and an increased risk to
post-ERCP pancreatitis. Therefore we reviewed each potential risk
based on the best available evidence to date.
Endoscopic retrograde cholangiopancreatography (ERCP):
patient selection and indications
ERCP is currently established as an essentially therapeutic
technique and, in pregnancy, it becomes even more pressing that it
is performed for this purpose alone. In this population, it is
indicated, as treatment in biliary pancreatitis, symptomatic
choledocholithiasis and cholangitis or in the lesions of the
pancreatic or biliary duct [10]. The usual risks associated with
ERCP, such as perforation, infection, hemorrhage and pancreatitis
can have important consequences to both mother and fetus. The
fear of inducing irreversible lesions postponed ERCP use for many
years in pregnant women.
Nonetheless, it is also relevant to refer that the conservative
approach for some of these indications can also be deleterious. As
showed in a retrospective study, the conservative management
(versus ERCP and/or surgery) of cholelithiasis and its complications
in pregnancy is significantly associated with higher recurrent
biliary symptoms, number of emergency department visits,
number of hospitalizations and cesarean section operations for
childbirth [11].
Risks of radiation exposure and strategies of reduction
Fluoroscopy radiation may have both stochastic effects and
deterministic effects. The formers, do not present a dose threshold,
the likelihood of developing deleterious effects is proportional to
the dose but its severity is dose-independent (e.g. leukemia). In the
latters, the dose and severity threshold are proportional to the dose
(e.g. cataracts) [12]. Hence the concept “as low as reasonably
achievable” radiation has emerged [13]. In fact, the European
Society of Digestive Endoscopy (ESGE) recommends in its radiation
protection guideline that KAP (kerma-area product) should be
monitored, and its cumulative value should be recorded for every
ERCP and patient [14].The American College of Obstetricians and Gynecologists
(ACOG) has stated in 2016 diagnostic imaging guidelines that:
“Fetal risk of anomalies, growth restriction, or abortion have not
been reported with radiation exposure of less than 50 mGy, a level
above the range of exposure for the diagnostic procedures.”15 In
fact, in a study involving 17 ERCPs in pregnant women with a mean
fluoroscopy time of 14 s (range 1–48 s), the estimated fetal
radiation exposure was 0.40 mGy (range 0.01–1.8 mGy). There
was a correlation between fluoroscopy time and radiation
exposure, but there was a wide range of exposure for individual
fluoroscopy times [16]. In another study, the estimated fetal
radiation was 1.02–5.77 mGy (0.00102–0.00577 Gy) [17]. The
International Commission on Radiological Protection (ICRP)
recommends monitoring fetal radiation when a dose is expected
to exceed 0.01 Gy [18] Studies in clinical practice have estimated
fetal radiation induced by ERCP of <0.1–5.77 mGy (0.0001–
0.006 Gy). Although measurements show low fetal absorbed dose
values (clearly below ICRP radiation cutoff), methodologies also
demonstrate that minute variations in the procedure including
degree of incidence of fluoroscopy, position of the patient,
orientation of the fetus and endoscopist experience can have
dramatic effects on the final dose absorbed [19].
The risk to the fetus is also dependent on the gestational age.
Based on data from atomic bomb survivors, it appears that the risk
to the central nervous system is greatest when the exposure occurs
at 8–15 weeks of gestation. It has been suggested that the
minimum dose for this adverse effect might be 60–310 mGy but
the lowest recorded dose to induce severe intellectual disability
was 610mGy. After 16 weeks there is a low risk for intellectual
disability. [15]
In a study involving 23 pregnant patients submitted to a total of
29 ERCPS, 3 women did not know that they were pregnant [20]. It is
important to confirm with all women of childbearing age if they are
pregnant at the time of the procedure due to the risks in early
pregnancy. Before implantation (0–2 weeks after conception), with
a minimum dose of 50–100 mGy the effect can be “all or none”:
death of embryo or no consequence. During organogenesis (2–8
weeks) the estimated threshold dose is 200 mGy for congenital
anomalies (skeleton, eyes, genitals) and growth restriction [15].
Fetal radiation exposure depends on multiple factors such as
size and body composition of the mother, gestational age as
discussed, position of the mother and fetus and exposure
techniques. The use of a lead apron placed inferiorly to the pelvis
and lower abdomen of the pregnant woman is recommended
although most of the exposure of fetal radiation comes from
radiation diffused by the mother, so it is essential to complement
this protection with other strategies [16].
There are several strategies to reduce the radiation exposure to
the mother and fetus during fluoroscopy: use as little fluoroscopy
time and obtain as few spot exposures as possible; keep the image
intensifier as close to the patient as possible; use Boost Mode and
Magnification Mode only when necessary; use a modern
fluoroscopy equipment; collimate x-ray beam to the area of
interest and use a low frame-rate. In manual mode, use higher kV
(at least 75) and lower mA settings (decrease in patient dose of 50%
can be achieved by increasing voltage from 75 kV to 96 kV).
Monitoring and recording the amount of fluoroscopy time is
another strategy to increase awareness of the endoscopist and
reduce the total exposure time [13].
Amniotic fluid is a possible conductor of current to the fetus.
Thus, the uterus should not be between the grounding pad and the
electrical catheter. The pad should be placed higher in the posterior
thoracic wall (rather than the hip). Bipolar electrocautery should
be preferred, to minimize this risk [10].
National Radiological Protection Board advises magnetic
resonance imaging (MRI) avoidance during the first trimester
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critical risk-benefit analysis and only if the diagnostic information
cannot be provided by ultrasound [21]. This recommendation is
based on theoretical possible biological effects and there are no
harmful reports of MRI during pregnancy known until the date of
writing.
ERCP complications
A retrospective cohort study of the National Inpatient Sample
with 907 pregnant and 2721 non-pregnant women demonstrated
that there was no difference in rates of perforation, infection and
bleeding of ERCPs performed in pregnant women. Post-ERCP
pancreatitis (PEP) occurred in 12% of pregnant women vs. 5% non-
pregnant. Pregnancy was an independent risk factor (OR 2.8, CI
2.1–3.8) for PEP [22]. The pregnancy group had less pancreatic
stents placed than the control group, which was statistically
significant. Nevertheless, even after adjusting for the stents,
pregnancy was still an independent factor. The authors suggested
several possible mechanisms for this: the tendency to use the least
radiation possible could lead to more difficult cannulation; the
physicians could be less prone to give large volumes of intravenous
fluid during/after ERCP or to treat with NSAIDs (nonsteroidal anti-
inflammatory drugs) which can be teratogenic. There could also be
a physiologic mechanism that inherently predisposed pregnant
women to PEP. However, the authors emphasize that ERCP should
not be discouraged in pregnant women with clear indication. It is
still the least-invasive approach to therapy for bile duct pathology
(vs. surgical or radiologic management).
Another unicenter retrospective study had previously sug-
gested this hypothesis with PEP in 16% of the 68 ERCPs performed
on 65 pregnant [23].
Non-radiation ERCP
In a retrospective study, 21 ERCPs without fluoroscopy were
analyzed in pregnant women [24]. A previous imaging study was
performed (all had abdominal ultrasound, 6 echoendoscopy (EUS)
and 4 magnetic resonance cholangiopancreatography (MRCP)).
The bile cannulation was confirmed by the observation of bile
around the guidewire (with forward and backward movements).
When bile was not visible, a 5 French (Fr) 2 cm stent was placed. In
the case of drainage of bile by the stent, sphincterotomy was
performed with needle-knife followed by cannulation and stent
removal. In case of drainage of pancreatic juice, access papillotomy
was performed. Peroral cholangioscopy (Spyglass1) was used to
confirm technical success in 5 cases without previous EUS/MRCP.
One case of PEP was reported (catheter advancement prior to
cannulation confirmation) but there was no symptomatic recur-
rence in any of the cases.
A two stage ERCP approach has been described in a study
involving 11 pregnant women [25]. ERCP was performed without
fluoroscopy or EUS. All the women presented with jaundice and
pain, registering 2 cases of cholangitis. In a first time, the initial
sphincterotomy was performed with stent placement without
using fluoroscopy. After delivery, ERCP was performed with
lithiasis extraction. In this second ERCP, 1 case presented no
lithiasis, 8 cases with stones with 5–8 mm removed with Dormia
basket, and 2 cases with stones >15 mm (1 resolved with
extracorporeal lithotripsy and 1 surgically). All deliveries were
of term, with no need for rehospitalization and no changes in
infant development during the follow-up period up to 6 years. A
similar two-stage intervention was carried in a retrospective study
involving 17 third-trimester pregnancies (34 ERCPS): 7 cases with
endoscopic nasobiliary drainage and 10 with bile duct plastic stent
[26]. There were two complications, namely, one biliary tracthemorrhage and one case of acute mild pancreatitis. All symptoms
were significantly alleviated. Eleven cases had term labors and 6
had premature delivery.
The strategy of only placing a stent has the advantage of
fluoroscopy being minimal but carries a risk of migration or
occlusion of the stent that could cause cholangitis and need for
another ERCP. Performing only sphincterotomy facilitates the
passage of stones and is preferable to stent only but might not be
sufficient to maintain decompression until postpartum cholecys-
tectomy [25].
In a retrospective study, Vohra et al. demonstrated the
successful single-session endosonography-based ERCP without
fluoroscopy in 10 pregnant patients with suspected choledocoli-
thiasis [27]. IDUS (miniprobe intraductal ultrassound) was not
used given the need for fluoroscopy. EUS excluded choledocho-
lithiasis in 4 cases, thus avoiding ERCP. Lithiasis was confirmed in
the remaining 6 cases, the number of bile stones extracted being
equal to the number visualized in the EUS. Bile cannulation was
confirmed by aspiration of bile. A numbered guidewire was used to
monitor the progression inside the bile duct endoscopically. Biliary
sphincterotomy with endocut mode was performed, followed by
stone extraction using a standard Dormia basket. Cholangioscopy
was used in two patients given the fragmentation of lithiasis to
confirm complete extraction. There were no complications,
repetition of procedures, adverse events or abortions.
These results support the studies of single session EUS-ERCP in
non-pregnant patients, demonstrating that ERCP can be safely
avoided in a significant number of patients (44–75%, depending on
the risk stratification for suspected choledocholithiasis of the
patients) [28,29].
Nonradiation ERCP with endoscopic biliary sphincterotomy
plus papillary balloon dilation was retrospectively evaluated for
the treatment of choledocholithiasis in 22 pregnant patients.
Balloon dilation was performed with a 6-mm balloon in 17 patients
and an 8-mm in five patients, according to the diameter of the CBD
(common bile duct) on US (ultrasonography) or MRCP, with
effective stone extraction in 18 patients. No biliary stent was used.
All patients delivered at term, and none experienced recurrence of
symptoms during the 6-month follow-up. There were 2 cases of
PEP [30].
Failed cannulation while performing ERCP during pregnancy is
a technically demanding situation. There has been a case report of a
successfully attempted EUS guided rendezvous technique, with
fluoroscopy used only to confirm the exit of the wire from ampulla,
wire reposition in intrahepatic biliary system and the position of
the stent. The whole fluoroscopy exposure time was 3 s [31].
ERCP timing
There is the generic recommendation to avoid endoscopy in the
first trimester whenever possible [10]. In ERCP, there has also been
worries during the first trimester. In a retrospective review of 68
ERCPs performed in 65 pregnant patients, there were no
perforation, sedation adverse events, postsphincterotomy bleed-
ing, cholangitis, or procedure-related maternal or fetal deaths.
However, women submitted to ERCP in the first trimester had the
lowest percentage of term pregnancies (73%), the highest risk of
preterm delivery (20%) and low birth weight newborns (21%) [23].
However, the authors suggested that it was the development of
hepatobiliary disease in the first trimester of pregnancy that could
be associated with preterm delivery or low birth weight and not
the procedure itself. They suggested therefore “to intervene
appropriately as early as possible”.
In fact, as showed in a retrospective study of 112 pregnant
women, the conservative management (versus ERCP and/or
surgery) of cholelithiasis and its complications (mainly biliary
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thiasis) in pregnancy is significantly associated with higher
cesarean section operations for childbirth and higher recurrent
biliary symptoms, number of emergency department visits and
number of hospitalizations [11]. ERCP was performed at a mean of
3.7 days after the onset of the symptoms by experienced endo-
scopists. CBD cannulation rate was 100% and biliary sphincter-
otomy was done in 88%. Only one complication was reported, one
case of PEP that resolved in a few days with conservative
management. But it is important to refer that this study included
only 4 ERCP in the first trimester. Another study, demonstrated that
up to 72% of pregnant women with biliary pancreatitis will have an
intercurrence during pregnancy if a conservative approach is taken
[32].
In a retrospective matched-cohort study with 907 ERCP
performed in pregnant women, there is no reference to the
trimesters or week of gestation. Nevertheless, there were no
differences in maternal mortality, fetal distress or fetal loss when
compared to age-matched pregnant women. Curiously, the risk of
preterm labor in pregnant patients undergoing ERCP was lower
than the national average [22].
Finally, the evidence is scarce relating specifically to the best
timing for each indication. Taking into account the aforementioned
studies, ERCP should not be deferred in cases of cholangitis, biliary
pancreatitis and symptomatic choledocholithiasis. Each case
should be discussed with the obstetrician to proceed with ERCP
even in the first trimester. Lesions of the pancreatic or biliary duct
should be evaluated case-by-case in terms of urgency of the
procedure. When the event occurs in the third trimester, the timing
of delivery should be discussed with the obstetrician to decide
between an early delivery and ERCP post-partum or ERCP in the
third trimester, considering that ERCP is a safe procedure in third
trimester.
Cholecystectomy
Surgery during pregnancy increases the risk of fetal loss.
Therefore, the indication is usually limited to urgent situations as
acute cholecystitis. The second trimester is considered to be the
optimal time for cholecystectomy, with the lowest risk for fetal
morbity [33]. However, there are also several studies demonstrat-
ing the safety in urgent cases during the first trimester [34].
Surgery in the third trimester was generally limited for fear of
induction of preterm labor (up to 40% in initial studies). Most
recent studies limited to laparoscopic approach have shown that
surgery is safe in any trimester without significant increased risk
[35].
Women who have complicated gallstone are unlikely submitted
to cholecystectomy during pregnancy. Nevertheless, the risk of
symptom recurrence either during pregnancy or in the early post-
partum is higher when cholecystectomy is not performed. ERCP
with biliary sphincterotomy significantly reduces this risk [36].
Cholecystectomy should be considered in complicated gallstone
disease during pregnancy, especially in patients that do not
undergo or fail ERCP with biliary sphincterotomy. The value of
intrapartum cholecystectomy after ERCP has not been specifically
studied, but the small studies of ERCP during pregnancy previously
stated suggest that endoscopic sphincterotomy may be sufficient
to prevent recurrence during pregnancy [24,25,30]. Likewise,
laparoscopic cholecystectomy could be safely done immediately
postpartum in these patients.
Conclusion
ERCP can be performed in pregnancy safely and effectively in
women who have a clear indication. There are multiple strategiesfor reducing maternal and fetal risks associated with this
technique.
EUS can eliminate the need for ERCP and its risks in pregnant
women with no concrete evidence of choledocholithiasis, and even
plan the best approach in those that present previous evidence by
specifying the number, size and location of the lithiasis. EUS-CPRE
thus presents itself as the ideal approach in pregnancy. The use of a
linear EUS scope for the entire procedure has already been
described. Also, the two-step strategy proved to be a safe and
effective alternative without the need for fluoroscopy. However,
stent placement increases the risk of recurrence of ERCP, so the
risks of repetition of the procedure should be weighed against
controlled radiation exposure from a single ERCP. Whichever
method is used, it should be combined with other radiation
reduction strategies in ERCP, namely: a lead apron placed inferiorly
to the pelvis and lower abdomen of the pregnant; as little
fluoroscopy time and as few spot exposures as possible; image
intensifier as close to the patient; dismiss boost and magnification
modes; collimate x-ray beam and use low frame-rate; use higher
kV and lower mA settings. Monitoring and recording the amount of
fluoroscopy time is encouraged and the procedure should be done
by an experienced endoscopist.
There are no prospective studies to quantify the superiority of
EUS-ERCP in the different outcomes and demonstrate cost-
effectiveness versus other approaches. However, given the small
series and the rarity of the procedure compared to other
populations, this is a level of evidence difficult to achieve.
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